Lab Manager | Zist Fanavari Novin Biotechnology Institute | Iran
Dr. Mansoureh Azadeh is a distinguished molecular and cellular biologist and the Founder and Director of Zist Fanavari Novin Biotechnology Institute in Isfahan, Iran. With over two decades of leadership in academia, research, and biotechnology entrepreneurship, she has significantly advanced cancer genomics, gene expression analysis, and personalized medicine. Her research spans diverse areas including breast cancer, cardiovascular disease, multiple sclerosis, drug resistance, and athletic genomics. In 2023, she founded PreventiGene, a genetics startup focused on early cancer detection. Dr. Azadeh has served as Chair of the Board at Control Tavan Novin Pouya since 2006, and has also managed the COVID-19 department at Jey Medical Diagnosis Laboratory. An active educator, she has taught for 20 semesters at Azad University and leads national technical training programs in biotechnology. She has authored books on laboratory methods and cancer diagnostics, serves as an editor for medical journals, and regularly collaborates with academic and industry partners to promote scientific innovation. She is widely recognized for her expertise in advanced technologies such as CRISPR, RNA sequencing, and high-throughput data analysis, and has developed and supervised numerous genetic research initiatives. Her technical skills span PCR/qPCR, ELISA, Western blotting, microbiology, and cell culture. As of October 2025, Dr. Azadeh has authored 34 indexed publications, with 313 citations, and holds an h-index of 13 , reflecting her impactful contribution to life sciences and translational research.
Profiles: Scopus | Google Scholar | LinkedIn | ResearchGate
Featured Publications
1. Bagheri, F., Mesrian Tanha, H., Mojtabavi Naeini, M., Ghaedi, K., & Azadeh, M. (2016). Tumor-promoting function of single nucleotide polymorphism rs1836724 (C3388T) alters multiple potential legitimate microRNA binding sites at the 3′-untranslated region of ErbB4. Molecular Medicine Reports, 13(5), 4494–4498.
Cited by: 39
2. Ebrahimi Ghahnavieh, L., Tabatabaeian, H., Ebrahimi Ghahnavieh, Z., & others. (2020). Fluctuating expression of miR-584 in primary and high-grade gastric cancer. BMC Cancer, 20, 621.
Cited by: 31
3. Noormohammad, M., Sadeghi, S., Tabatabaeian, H., Ghaedi, K., Talebi, A., & others. (2016). Upregulation of miR-222 in both Helicobacter pylori-infected and noninfected gastric cancer patients. Journal of Genetics, 95(4), 991–995.
Cited by: 29
4. Fattahi Dolatabadi, N., Dehghani, A., Shahand, E., Yazdanshenas, M., & others. (2020). The interaction between MALAT1 target, miR-143-3p, and RALGAPA2 is affected by functional SNP rs3827693 in breast cancer. Human Cell, 33(4), 1229–1239.
Cited by: 28
5. Adami, B., Tabatabaeian, H., Ghaedi, K., Talebi, A., Azadeh, M., & Dehdashtian, E. (2019). miR-146a is deregulated in gastric cancer. Journal of Cancer Research and Therapeutics, 15(1), 108–114.
Cited by: 28
